After a nine-year delay, federal officials in April 2019 did as Congress ordered and began posting 340B ceiling prices on a secure website. For the first time, providers enrolled in the 340B program had a tool to help them make sure they were not being overcharged.
Providers and their allies “praise the database as an essential tool to help ensure pricing accuracy,” 340B Report Publisher and CEO Ted Slafsky says in his latest blog post for Omnicell. Drug manufacturers’ public notices about refunds for 340B overcharges are way up, he notes. Federal auditors are finding more evidence of 340B overcharges—a sign the government uses the new system to check for and act on pricing discrepancies.
Providers and their allies praise the 340B ceiling price secure website, but it has limitations and can be made even better, 340B Report Publisher and CEO Ted Slafsky says in his latest blog post for Omnicell.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
